| Not Yet Recruiting | Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metast NCT06093425 | Suzhou Transcenta Therapeutics Co., Ltd. | Phase 3 |
| Not Yet Recruiting | Integrated Smartphone Technology to Alleviate Malignant Pain (I-STAMP) Testing NCT06117709 | Dana-Farber Cancer Institute | N/A |
| Recruiting | A Pilot Randomized Controlled Trial of a Social Network Intervention NCT07393529 | University of Rochester | N/A |
| Not Yet Recruiting | An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers NCT07426757 | Pfizer | Phase 1 |
| Not Yet Recruiting | Resilience-Building for Advance Care Planning NCT07428278 | University of Illinois at Chicago | N/A |
| Not Yet Recruiting | A Feasibility Study of Death Education Intervention for Family Caregivers of Advanced Cancer Patients NCT07367984 | The Hong Kong Polytechnic University | N/A |
| Recruiting | Methods of Identifying Effective Off-Guideline Treatments for Advanced Cancer Patients (CC N-of-1) NCT07343024 | Cancer Commons | — |
| Recruiting | Electronic Patient Reporting of Symptoms and Unmet Needs to Connect Patients With Advanced Cancer to Palliativ NCT07195513 | Dartmouth-Hitchcock Medical Center | N/A |
| Recruiting | Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss NCT07382544 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer NCT07432295 | I-Mab Biopharma US Limited | Phase 2 |
| Not Yet Recruiting | Trial of Spiritual Care Interventions for Patients With Cancer NCT07408310 | Weill Medical College of Cornell University | N/A |
| Recruiting | A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of T NCT07269145 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 |
| Recruiting | A Chaplain-clinician Led Spiritual Care (PEACE) Intervention on Spiritual/Religious Beliefs Related to Medical NCT07246954 | M.D. Anderson Cancer Center | N/A |
| Recruiting | Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas NCT06346197 | Centre Leon Berard | Phase 3 |
| Not Yet Recruiting | A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients Wit NCT07269158 | Yonsei University | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3217 T NCT07291050 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 |
| Recruiting | A Study of PHN-012 in Patients With Advanced Solid Tumors NCT07127874 | Pheon Therapeutics | Phase 1 |
| Active Not Recruiting | Better Real-time Information on Documentation of Goals of Care for Engagement in Serious Illness Communication NCT07147023 | Dana-Farber Cancer Institute | N/A |
| Recruiting | Care Coach-led Integrated Palliative Surgical Oncology and Rehabilitation Care Model for Advanced Cancer Patie NCT07133269 | Singapore General Hospital | N/A |
| Recruiting | Development and Pilot Trial of Focused ACT (FACT) for Patients With Advanced Cancer NCT07105033 | M.D. Anderson Cancer Center | N/A |
| Recruiting | Development of an Educational Patient Decision Aid (Treatments in Advanced Cancer - Decision Aid, TA-DA) to Pr NCT07009886 | M.D. Anderson Cancer Center | N/A |
| Recruiting | Study of HC006 in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors NCT06963814 | HC Biopharma Inc. | Phase 1 |
| Recruiting | Practical Geriatric Assessment (PGA) Implementation Strategies and Correlative Evaluations (PACE-70) NCT06870617 | Abramson Cancer Center at Penn Medicine | — |
| Recruiting | Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer NCT06963723 | Alliance Foundation Trials, LLC. | N/A |
| Recruiting | Kinesio-Taping vs. Usual Care for Malignant Bowel Obstruction With Ascites NCT07023042 | National Taiwan University Hospital | N/A |
| Not Yet Recruiting | Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer NCT07003815 | Tongji Hospital | Phase 2 |
| Withdrawn | Dyadic Text-Messaging Micro-Intervention NCT05917990 | Duke University | N/A |
| Recruiting | BOLSTER: Learning New Skills to Thrive NCT06936878 | Dana-Farber Cancer Institute | N/A |
| Not Yet Recruiting | Nurses' Competence and Role in Survival Prediction and Prognostic Communication NCT06962553 | National Taiwan University Hospital | — |
| Recruiting | Integrating Pain-CBT Into an mHealth Analgesic Support Intervention for Patients With Chronic Pain From Advanc NCT06722014 | Dana-Farber Cancer Institute | N/A |
| Not Yet Recruiting | Implementation of the Caregivers-Patients Support Coping with Advanced-Cancer (CASA) Intervention. NCT06883058 | Ponce Medical School Foundation, Inc. | N/A |
| Recruiting | ALIGN for Older Adults With Cancer in SNFs NCT06616298 | University of Colorado, Denver | N/A |
| Not Yet Recruiting | Using Tumor Models to Determine Treatments NCT06813079 | University Health Network, Toronto | Phase 2 |
| Recruiting | Pilot Trial of Spiritual Care Interventions for Patients With Cancer NCT06811376 | Weill Medical College of Cornell University | N/A |
| Recruiting | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Parti NCT06707610 | Shanghai Allink Biotherapeutics Co., Ltd. | Phase 1 |
| Recruiting | SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization NCT06389097 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | — |
| Completed | Behavioral Activation-Led Activity Engagement for Cancer Empowerment NCT06796608 | University of Pittsburgh | N/A |
| Recruiting | HAIC Combined With Immune Therapy for Advanced, Non-Resectable ICC NCT07364305 | Eastern Hepatobiliary Surgery Hospital | Phase 2 |
| Recruiting | Clinical Trial of TQB3002 in Patients With Advanced Cancers NCT06662760 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 |
| Not Yet Recruiting | A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss NCT06614751 | Danatlas Pharmaceuticals Co., Ltd | Phase 1 |
| Recruiting | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Parti NCT06656390 | Shanghai Allink Biotherapeutics Co., Ltd. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Molecular Services and EMR-Lab Integration Application (ELIA) for Reducing Healthcare Disparities in Cancer Pa NCT06090513 | Bien-Willner Physicians Group PA | — |
| Not Yet Recruiting | Telemedicine in Palliative Care: Interventions, Experiences and Perceptions of Patients Diagnosed With Cancer NCT06538350 | OncoHelp Association | N/A |
| Recruiting | Psilocybin in Cancer Pain Study NCT06001749 | Yvan Beaussant, MD, MSci | Phase 2 |
| Terminated | A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic So NCT06540066 | BeiGene | Phase 1 |
| Completed | A Phase I Study on Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Effica NCT06736275 | Jiangsu Nutai Biologics Co., Ltd | EARLY_Phase 1 |
| Recruiting | A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy NCT06362369 | 7 Hills Pharma, LLC | Phase 1 / Phase 2 |
| Recruiting | A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Soli NCT06440005 | Angiex, Inc. | Phase 1 |
| Terminated | A Study of PHN-010 in Patients With Advanced Solid Tumors NCT06457997 | Pheon Therapeutics | Phase 1 |
| Recruiting | A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or NCT06548672 | Biocity Biopharmaceutics Co., Ltd. | Phase 1 |
| Recruiting | A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors NCT06190886 | Proviva Therapeutics, Inc. | Phase 1 |
| Active Not Recruiting | Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer NCT06416085 | University Health Network, Toronto | Phase 2 |
| Active Not Recruiting | Efficacy of a Proactive Approach to Death Thoughts in People With Advanced Cancer NCT06420609 | Universitat Internacional de Catalunya | N/A |
| Not Yet Recruiting | Effect and Safety of Ocoxin Oral Solution on the Quality of Life of Paediatric Patients With Advanced Stage So NCT06363201 | Catalysis SL | N/A |
| Recruiting | A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs NCT06228326 | Krystal Biotech, Inc. | Phase 1 / Phase 2 |
| Recruiting | NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC NCT06405490 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Recruiting | Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy NCT06200155 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Analysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic NCT06227728 | Gene Solutions | — |
| Recruiting | Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cance NCT06338683 | Qinghai Red Cross Hospital | Phase 3 |
| Active Not Recruiting | Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer NCT06107868 | University Health Network, Toronto | Phase 1 |
| Recruiting | A Study of MGC026 in Participants With Advanced Solid Tumors NCT06242470 | MacroGenics | Phase 1 |
| Recruiting | Personalized Neoantigen Peptide Vaccines for Solid Tumors NCT07002203 | Seqker Biosciences, Inc. | Phase 1 / Phase 2 |
| Terminated | A Mass Balance Study of [14C]-Nanatinostat and Relative Bioavailability Study of Nanatinostat in Patients With NCT06302140 | Viracta Therapeutics, Inc. | Phase 1 |
| Recruiting | First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer NCT06239467 | OnKure, Inc. | Phase 1 |
| Active Not Recruiting | Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) NCT05853575 | Mirati Therapeutics Inc. | Phase 2 |
| Recruiting | Assessment of the Quality and Sexual Health Needs of Patients with Advanced-stage Cancer NCT06229158 | Hospices Civils de Lyon | — |
| Recruiting | Umbrella Study for Single Patient Treatments in Oncology NCT06285500 | University Health Network, Toronto | — |
| Recruiting | Clinical Trial of TQB2922 for Injection in Patients With Advanced Cancers NCT06188624 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | Evaluating Disparities in Precision Oncology NCT06081517 | Indiana University | — |
| Active Not Recruiting | A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies NCT06120075 | Arcus Biosciences, Inc. | Phase 1 |
| Recruiting | A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH) NCT06210776 | Daiichi Sankyo | — |
| Recruiting | A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologi NCT06215950 | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| Recruiting | A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s) NCT06174987 | Daiichi Sankyo | Phase 3 |
| Unknown | FOCUSau: A Dyadic Digital Health Intervention to Improve the Wellbeing of People With Advanced Cancer and Thei NCT06082128 | University of Melbourne | N/A |
| Recruiting | A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumo NCT06010875 | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| Completed | Prognostic Understanding in ESC (ProgESC Study) NCT06067087 | University College, London | — |
| Enrolling By Invitation | Community Health Worker Based Intervention to Improve Palliative Care NCT05407844 | Wake Forest University Health Sciences | N/A |
| Unknown | Clinical Study on the Treatment of Advanced Recurrent Tumors With Anticancer Mouse Characteristic Human Neutro NCT06240767 | Wuxi People's Hospital | Phase 1 |
| Not Yet Recruiting | Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib NCT05988697 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | — |
| Active Not Recruiting | Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers NCT05891171 | Arcus Biosciences, Inc. | Phase 1 |
| Recruiting | Phase 1 Study of AWT020 in Advanced Cancer NCT06092580 | Anwita Biosciences | Phase 1 |
| Recruiting | Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types NCT05877430 | CJ Bioscience, Inc. | Phase 1 / Phase 2 |
| Completed | Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractor NCT05990920 | NKGen Biotech, Inc. | Phase 1 |
| Terminated | Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Can NCT05840510 | Mirati Therapeutics Inc. | Phase 1 |
| Recruiting | Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer NCT07062263 | Tata Memorial Centre | Phase 3 |
| Unknown | Acceptance and Commitment Therapy on Fatigue Interference in Patients With Advanced Lung Cancer and Caregiver NCT05885984 | Chinese University of Hong Kong | N/A |
| Recruiting | Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients NCT05663710 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Unknown | TQB2223 Injection in Combination With Penpulimab in Patients With Advanced Cancers NCT05894421 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 |
| Completed | Study of the Life Stories of Patients Making a Request for Euthanasia, in the Context of Advanced Cancer. NCT05884788 | Centre Leon Berard | — |
| Active Not Recruiting | A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid NCT05864144 | Sensei Biotherapeutics, Inc. | Phase 1 / Phase 2 |
| Completed | RP-6306 in Patients With Advanced Cancer NCT05605509 | Canadian Cancer Trials Group | Phase 2 |
| Recruiting | Psilocybin Therapy in Advanced Cancer NCT05398484 | NYU Langone Health | Phase 2 / Phase 3 |
| Recruiting | A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer NCT05859074 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Recruiting | POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC NCT05782361 | Institute of Cancer Research, United Kingdom | Phase 1 |
| Active Not Recruiting | Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers NCT05749549 | Shanghai Blueray Biopharma Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced C NCT05735080 | Incyclix Bio | Phase 1 / Phase 2 |
| Active Not Recruiting | Clinical Trial of the TQB2102 Injection in Patients With Advanced Cancers NCT05735496 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 1 |
| Terminated | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours NCT05714553 | NuCana plc | Phase 1 / Phase 2 |
| Recruiting | High Definition Medicine for Solid Tumors Oncology NCT06590506 | Centro Nacional de Investigaciones Oncologicas CARLOS III | — |
| Active Not Recruiting | A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Ad NCT05076552 | Tachyon Therapeutics, Inc. | Phase 1 |
| Unknown | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Cervical and End NCT05812677 | Shanghai Yunying Medical Technology | EARLY_Phase 1 |
| Unknown | The Value of Molecular Residual Disease Monitoring Based on ctDNA in Advanced or Metastatic Pancreatic Cancer NCT05802420 | Peking Union Medical College Hospital | N/A |
| Unknown | Home And Locally Observed - Tracking (HALO-Trak) NCT05971277 | University College, London | — |
| Unknown | AMT-151 in Patients With Selected Advanced Solid Tumours NCT05498597 | Multitude Therapeutics Inc. | Phase 1 |
| Active Not Recruiting | SUPPORT+ Digital Self-Management and Clinical Support for Advanced Cancer NCT07475312 | The University of Hong Kong | N/A |
| Completed | The Science of the Art of Palliative Care NCT05137782 | Dartmouth-Hitchcock Medical Center | N/A |
| Completed | 90-Day Mortality After Emergency Department Discharge in Advanced Cancer NCT07167095 | Ankara Etlik City Hospital | — |
| Recruiting | Evaluating Personalized Therapeutics Clinic (PTC) on Drug-Drug Interactions and Drug-Gene Interactions NCT05166694 | University of Chicago | N/A |
| Terminated | Oral AMXT 1501 Dicaprate in Combination With IV DFMO NCT05500508 | Aminex Therapeutics, Inc. | Phase 1 / Phase 2 |
| Completed | Oral Administration of STC-15 in Subjects With Advanced Malignancies NCT05584111 | STORM Therapeutics LTD | Phase 1 |
| Recruiting | A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitog NCT05557045 | Jazz Pharmaceuticals | Phase 1 |
| Recruiting | Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors NCT05394103 | Qurient Co., Ltd. | Phase 1 / Phase 2 |
| Terminated | TT-816 As Monotherapy or in Combination with a PD-1 Inhibitor in Patients with Advanced Cancers (SEABEAM) (MK3 NCT05525455 | Teon Therapeutics, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients NCT05375994 | Verastem, Inc. | Phase 1 / Phase 2 |
| Recruiting | Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors NCT05270213 | Riboscience, LLC. | Phase 1 |
| Completed | STAMP+CBT mHealth for Cancer Pain NCT05403801 | Dana-Farber Cancer Institute | N/A |
| Suspended | Safety and Efficacy of Inhaled Synthetic THC/CBD for Improving Physical Functioning and for Modulating Cachexi NCT04001010 | Tetra Bio-Pharma | Phase 3 |
| Recruiting | Actinium 225 Labeled Anti-CEA Antibody (Ac225-DOTA-M5A) for the Treatment of CEA Producing Advanced or Metasta NCT05204147 | City of Hope Medical Center | Phase 1 |
| Recruiting | A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy NCT05276310 | ImmuneOncia Therapeutics Inc. | Phase 1 |
| Terminated | A Study of DS-9606a in Patients With Advanced Solid Tumors NCT05394675 | Daiichi Sankyo | Phase 1 |
| Recruiting | CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma NCT05257590 | TaiRx, Inc. | Phase 2 |
| Recruiting | HALO Trial: Haloperidol vs Olanzapine in Hyperactive Delirium in Palliative Care Patients; A Multi-Centre, Ran NCT04833023 | Tan Tock Seng Hospital | Phase 3 |
| Completed | Patients Characteristics, Treatment Pattern & Outcomes of Patients With Advanced, Recurrent or Metastatic Endo NCT05364905 | ARCAGY/ GINECO GROUP | — |
| Completed | Protreat-Trial: Prophylactic Antiemetic Treatment of Opioid-induced Nausea and Vomiting (OINV) in Palliative C NCT05315999 | Gerhild Becker | Phase 2 |
| Completed | Impact of Music Therapy on Pain in Patients Treated for Advanced Cancer NCT05315427 | Institut du Cancer de Montpellier - Val d'Aurelle | N/A |
| Recruiting | MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors NCT05076760 | Memgen, Inc. | Phase 1 |
| Completed | A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors NCT05298592 | Bristol-Myers Squibb | Phase 1 |
| Withdrawn | JS001+IMP4297 in Patients With Advanced Cancer NCT05262842 | Shanghai Junshi Bioscience Co., Ltd. | Phase 1 |
| Recruiting | A Study in Patients With Advanced Cancers NCT05320588 | BiOneCure Therapeutics Inc. | Phase 1 / Phase 2 |
| Recruiting | ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab NCT05082259 | Institute of Cancer Research, United Kingdom | Phase 1 |
| Active Not Recruiting | Care Planning Framework in Advanced Cancer (ABC123) NCT05408507 | University of Colorado, Denver | N/A |
| Active Not Recruiting | Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in T NCT05103358 | Aadi Bioscience, Inc. | Phase 2 |
| Terminated | A Study Explore JS001+JS002 in Patients With Advanced Cancer NCT05128539 | Shanghai Junshi Bioscience Co., Ltd. | Phase 1 |
| Unknown | Clinical Trial of the TQB2928 Injection in Patients With Advanced Cancers NCT05192512 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 1 |
| Completed | A Feasibility Study of a Virtual Rehabilitation and Physical Activity Program for People With Advanced Cancer NCT05047042 | University of Alberta | N/A |
| Terminated | Study on Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignant Tumors NCT05154630 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal Cancer NCT05420519 | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| Completed | Care Transition Intervention for Hospitalized Patients With Advanced Cancer NCT05142345 | Massachusetts General Hospital | N/A |
| Recruiting | The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs NCT05159245 | Helsinki University Central Hospital | Phase 2 |
| Completed | Virtual Dignity Therapy for Palliative Care Patients With Advanced Cancer NCT05113199 | Mayo Clinic | N/A |
| Completed | Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antige NCT04837196 | Astellas Pharma Global Development, Inc. | Phase 1 / Phase 2 |
| Unknown | An Expanded Clinical Study of Triple Therapy for Refractory Solid Tumors That Failed First-line Treatment for NCT05438342 | Shanghai Pudong Hospital | N/A |
| Unknown | A Clinical Study of Intratumoral Administration of RT-01 in Patients With Advanced Solid Tumors NCT05136937 | Wuxi People's Hospital | Phase 1 |
| Recruiting | Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer NCT04146298 | Changhai Hospital | Phase 1 / Phase 2 |
| Active Not Recruiting | Phase II RCT of an Internet-adaptation of Managing Cancer and Living Meaningfully (iCALM) NCT04757155 | University Health Network, Toronto | N/A |
| Unknown | Advanced Cancer Patients' and Their Primary Caregivers' Willingness to Communicate About Advance Care Planning NCT05426330 | Jules Bordet Institute | — |
| Completed | A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors NCT05025085 | Agenus Inc. | Phase 1 |
| Active Not Recruiting | Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced No NCT04823377 | Institut Curie | N/A |
| Completed | A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors NCT04991480 | Artios Pharma Ltd | Phase 1 |
| Active Not Recruiting | Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tu NCT05060432 | iTeos Belgium SA | Phase 1 / Phase 2 |
| Completed | Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions NCT05045040 | Yosuke Uchitomi | N/A |
| Unknown | A Clinical Study of TQB3824 in Subjects With Advanced Cancer NCT05028218 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 |
| Active Not Recruiting | Safety and Feasibility of Surgery After Conversion Therapy for Locally Advanced and Advanced NSCLC NCT04945928 | Ruijin Hospital | N/A |
| Recruiting | A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer NCT05004116 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Withdrawn | Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA) NCT04943627 | Agenus Inc. | Phase 3 |
| Completed | Safety Study of Whole Body Hyperthermia for Advanced Cancer NCT04467593 | ElmediX | N/A |
| Terminated | Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14) NCT04975256 | Mirati Therapeutics Inc. | Phase 1 |
| Completed | Palliative Care Referral System (PCRS) for Cancer Patients With Advanced Disease NCT04936568 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | N/A |
| Unknown | The Role of Vitamin D3 Supplementation in Advanced Cancer Patients With Pain NCT05450419 | Chang Gung Memorial Hospital | N/A |
| Completed | Acceptance and Commitment Therapy in Patients With Advanced Lung Cancer NCT04869267 | Chinese University of Hong Kong | N/A |
| Unknown | GLYPALCARE STUDY - Multicenter, Randomized Study for Evaluating Continuous Glucose Monitoring (CGM) by Using F NCT04942756 | Antea Foundation | N/A |
| Recruiting | Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors NCT04900818 | I-Mab Biopharma US Limited | Phase 1 |
| Completed | A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory G NCT04861987 | Processa Pharmaceuticals | Phase 1 |
| Unknown | AST-021p Study in Advanced Solid Tumors NCT04864418 | Aston Sci. Inc. | Phase 1 |
| Completed | Balance, Activity and Quality of Life NCT04772690 | REHPA, The Danish Knowledge Centre for Rehabilitation and Palliative Care | N/A |
| Unknown | A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors NCT04859777 | Monopteros Therapeutics Inc. | Phase 1 |
| Unknown | Complete Versus Partial Preservation of Denonvilliers' Fascia on Urogenital Function in Locally Advanced Recta NCT04672603 | Sixth Affiliated Hospital, Sun Yat-sen University | N/A |
| Completed | Impact of Human-Animal Interactions on Children With Life-Threatening Conditions and Their Parents NCT04310345 | Vanderbilt-Ingram Cancer Center | N/A |
| Unknown | Efficacy and Safety of PVT-1 Treatment in Patients With Advanced Non-Small Cell Lung Cancer NCT04840004 | PlusVitech S.L. | Phase 2 |
| Active Not Recruiting | Lenvatinib in Locally Advanced Invasive Thyroid Cancer NCT04321954 | Massachusetts Eye and Ear Infirmary | Phase 2 |
| Completed | International Study to Evaluate Two Programs of Support for Patients With Advanced Cancer and Their Families NCT04626349 | Vrije Universiteit Brussel | N/A |
| Suspended | Study of Amblyomin-X in Advanced Solid Tumor NCT03120130 | União Química Farmacêutica Nacional S/A | Phase 1 |
| Unknown | Prediction of Drug Response Using an Ex Vivo Organ Culture (EVOC) on Fresh Human Tumour Samples From Metastati NCT04599608 | Imperial College London | — |
| Withdrawn | Implementing Acupuncture and Chinese Herbal Medicine Into Palliative Care NCT04584775 | Medical University of Graz | N/A |
| Recruiting | A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors NCT04657068 | Artios Pharma Ltd | Phase 1 / Phase 2 |
| Completed | Care Transition Intervention for Patients With Cancer NCT04640714 | Massachusetts General Hospital | N/A |
| Withdrawn | Sophie Pilot Implementation and Assessment NCT03904342 | Boston Medical Center | N/A |
| Completed | Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors NCT04678921 | I-Mab Biopharma US Limited | Phase 1 |
| Recruiting | FS222 First in Human Study in Patients With Advanced Malignancies NCT04740424 | invoX Pharma Limited | Phase 1 |
| Unknown | A Prospective Dose Finding Study of Iscador Infusion NCT04376931 | HaEmek Medical Center, Israel | Phase 1 / Phase 2 |
| Completed | Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor NCT04648254 | Qurient Co., Ltd. | Phase 1 |
| Active Not Recruiting | FS120 Phase 1/1b Study in Patients With Advanced Malignancies NCT04648202 | invoX Pharma Limited | Phase 1 |
| Completed | Cemiplimab in AlloSCT/SOT Recipients With CSCC NCT04339062 | Dana-Farber Cancer Institute | Phase 1 / Phase 2 |
| Completed | Coping Together: Couple-based Interventions for Cancer NCT04590885 | Duke University | N/A |
| Completed | Study of Circulating Tumor DNA (ctDNA) Kinetics in Immuno-oncology (IO-KIN) NCT04606940 | University Health Network, Toronto | — |
| Active Not Recruiting | A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid T NCT04419532 | Daiichi Sankyo | Phase 1 |
| Completed | Patient-caregiver Communication Intervention for Prognostic Understanding NCT03833817 | Weill Medical College of Cornell University | N/A |
| Unknown | Adjunctive Effect of Acupuncture for Advanced Cancer Patients With Palliative Care: a Three-arm Randomized Tri NCT04398875 | The University of Hong Kong | N/A |
| Recruiting | A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or M NCT04495296 | Suzhou Transcenta Therapeutics Co., Ltd. | Phase 1 / Phase 2 |
| Terminated | Study of GNX102 in Patients With Advanced Solid Tumors NCT04250597 | GlycoNex, Inc. | Phase 1 |
| Recruiting | Routine Evaluation of People Living With Cancer NCT04406662 | University of Edinburgh | — |
| Completed | Resilient Living Program for Patients With Advanced Cancer and Their Caregivers NCT04480008 | Mayo Clinic | N/A |
| Active Not Recruiting | Assessing the Immunogenicity of pING-hHER3FL NCT03832855 | Herbert Lyerly | Phase 1 |
| Unknown | Enhanced Supportive Care for Advanced Cancer Patients: Evaluation of Standardized Care Pathway NCT04407013 | Yonsei University | N/A |
| Terminated | NBE-002 in Patients With Advanced Solid Tumors NCT04441099 | NBE-Therapeutics AG | Phase 1 / Phase 2 |
| Active Not Recruiting | Meaning-Centered Intervention for Muslim Patients Who Are Being Treated for Advanced Cancer NCT04435444 | Memorial Sloan Kettering Cancer Center | N/A |
| Completed | Do Patients Want to Engage in Discussions Dedicated to Anticipating (DDA) Their Preferences of Care in the Eve NCT04308356 | Assistance Publique - Hôpitaux de Paris | — |
| Unknown | Toripalimab Combined With Axitinib as Neoadjuvant Therapy for Advanced/Metastatic Non-clear Cell Renal Cell Ca NCT04385654 | West China Hospital | Phase 2 |
| Active Not Recruiting | A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors NCT04396821 | Suzhou Transcenta Therapeutics Co., Ltd. | Phase 1 / Phase 2 |
| Completed | LY3214996 +/- HCQ in Pancreatic Cancer NCT04386057 | Kimberly Perez, MD | Phase 2 |
| Completed | Safety and Pharmacokinetic Study of CVM-1118 Extended-Release in Advanced Cancer Patients NCT04336124 | TaiRx, Inc. | Phase 1 |
| Recruiting | AIMS Cancer Outcomes Study NCT04495790 | Advanced Integrative Medical Science Institute | — |
| Completed | A Trial of ZL-1201 in Subjects With Advanced Cancer NCT04257617 | Zai Lab (Shanghai) Co., Ltd. | Phase 1 |
| Completed | Comprehensive Palliative Care for Cancer Patients in Vietnam NCT05103488 | Vietnam Palliative Health Care Society | N/A |
| Terminated | Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in NCT04270864 | Gustave Roussy, Cancer Campus, Grand Paris | Phase 1 |
| Completed | Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2) NCT04330664 | Mirati Therapeutics Inc. | Phase 1 |
| Active Not Recruiting | COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies NCT04354246 | Compugen Ltd | Phase 1 |
| Unknown | Primary Cyto-reductive Surgery Vs Neo-adjuvant Chemotherapy (NAC) in Epithelial Ovarian Cancer NCT04257786 | Assiut University | N/A |
| Unknown | Effect of Laser Acupuncture on Constipation in Patients With Advanced Cancer NCT04318808 | Chang Gung Memorial Hospital | N/A |
| Active Not Recruiting | Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof- NCT04095208 | Institut Bergonié | Phase 2 |
| Completed | First-In-Human Study of EOS884448 in Participants with Advanced Cancers. NCT04335253 | iTeos Therapeutics | Phase 1 |
| Completed | A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanc NCT04148937 | Eli Lilly and Company | Phase 1 |
| Completed | Pembrolizumab in Biliary Tract Cancer NCT03260712 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 |
| Completed | The Efficacy of Multisession Mindful Breathing in Symptom Reduction Among Patients With Advanced Cancers NCT05910541 | University Malaysia Sarawak | N/A |
| Completed | A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Therapies in Japanese Participants Wi NCT04071262 | Eli Lilly and Company | Phase 1 |
| Completed | A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Adva NCT04200963 | Ikena Oncology | Phase 1 |
| Completed | Videos for Advance Care Planning in Young Adults NCT04149704 | Dana-Farber Cancer Institute | N/A |
| Active Not Recruiting | Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who NCT03546426 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Phase 1 |
| Withdrawn | A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer NCT04158700 | Eli Lilly and Company | Phase 1 / Phase 2 |
| Unknown | Study of the Apatinib Combine With POF Versus POF in Gastric Cancer NCT04121039 | Fujian Cancer Hospital | Phase 2 |
| Unknown | Clinical Study of Granulocyte Infusion for Advanced Cancer NCT04124666 | Shanghai East Hospital | Phase 1 / Phase 2 |
| Completed | UC Health Care Planning Study NCT04012749 | University of California, Los Angeles | N/A |
| Completed | Exercise Prescription in Patients With Bone Metastases NCT03979118 | University of Dublin, Trinity College | — |
| Unknown | Integration of Palliative Care in an Oncology and Hematology Unit NCT04089306 | University Hospital, Strasbourg, France | — |
| Unknown | Decision Aid to Support Advanced Cancer Patients NCT04606238 | University Hospital Heidelberg | N/A |
| Completed | Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer NCT04121676 | Agenus Inc. | Phase 1 |
| Completed | Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Uroth NCT03980041 | Infinity Pharmaceuticals, Inc. | Phase 2 |
| Completed | Ketamine or Placebo in Patients With Major Depression and Advanced Cancer NCT04471818 | Instituto Nacional de Cancerologia de Mexico | Phase 1 / Phase 2 |
| Completed | Nutrition Assessment in Advanced Cancer Patients NCT06323135 | West China Hospital | — |
| Completed | An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid NCT03994601 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Completed | A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors NCT03954067 | Astellas Pharma Global Development, Inc. | Phase 1 |
| Completed | Phase 1 Study of PTX-100 in Patients With Advanced Malignancies With PTCL Expansion Cohort NCT03900442 | Prescient Therapeutics, Ltd. | Phase 1 |
| Active Not Recruiting | Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer NCT03909334 | Xiuning Le | Phase 2 |
| Completed | Effect of Fluconazole on PK of Fluzoparib in Healthy Male Subjects NCT04193319 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Unknown | Anlotinib Hydrochloride Versus Imatinib Mesylate in Locally Advanced, Unresectable or Metastatic Chordoma NCT04042597 | Peking University People's Hospital | Phase 2 |
| Completed | Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to NCT03941262 | NKGen Biotech, Inc. | Phase 1 |
| Completed | Variation in Cancer Centers' End-of-Life Quality NCT03780816 | Dartmouth-Hitchcock Medical Center | — |
| Unknown | Treatment of Carrying TP53 Harmful Mutations NCT03645200 | Tianjin Medical University Second Hospital | Phase 1 |
| Active Not Recruiting | TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiat NCT03833479 | Grupo Español de Investigación en Cáncer de Ovario | Phase 2 |
| Recruiting | A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and NCT03829254 | NuCana plc | Phase 1 / Phase 2 |
| Recruiting | Non Inferiority Study of Preoperative Chemotherapy Without Pelvic Irradiation for Rectal Cancer NCT03875781 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Unknown | Apatinib Plus SHR1210 in Advanced Mucosal Melanoma NCT03986515 | Henan Cancer Hospital | Phase 2 |
| Completed | Delay to Diagnosis in Digestive Cancerology by the General Practitioner Related to Covid-19 Pandemic Confineme NCT06118125 | University of Bordeaux | — |
| Terminated | A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer NCT03936959 | Eli Lilly and Company | Phase 1 |
| Unknown | Crizotinib in ALK Rearranged Non-small-cell Lung Cancer NCT04317651 | Fondazione Ricerca Traslazionale | — |
| Completed | A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies NCT03922204 | Merus B.V. | Phase 1 |
| Unknown | Body Composition Manipulation in CoLorectal cancEr (BiCyCLE): Neuromuscular Electrical Stimulation (NMES) NCT04065984 | London North West Healthcare NHS Trust | N/A |
| Completed | An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumo NCT03745807 | Bristol-Myers Squibb | Phase 1 |
| Completed | Impact of a Resource-based Life Review Intervention on Advanced Cancer Patients NCT04254926 | School of Health Sciences Geneva | N/A |
| Active Not Recruiting | Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer NCT03860272 | Agenus Inc. | Phase 1 |
| Unknown | Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metas NCT03775525 | Genzada Pharmaceuticals USA, Inc. | Phase 1 |
| Completed | Animal-Assisted Interactions in Children With Life-Threatening Conditions and Their Parents NCT03765099 | Vanderbilt-Ingram Cancer Center | N/A |
| Unknown | A Study of Pembrolizumab in Patients With Advanced Gynaecological Clear Cell Cancer NCT03425565 | University College, London | Phase 2 |
| Terminated | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent NCT03829501 | Kymab Limited | Phase 1 / Phase 2 |
| Unknown | Toripalimab as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors NCT03810339 | Sun Yat-sen University | Phase 2 |
| Active Not Recruiting | Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 NCT03785249 | Mirati Therapeutics Inc. | Phase 1 / Phase 2 |
| Completed | DM-CHOC-PEN for Brain Tumors in AYA Subjects NCT03668847 | DEKK-TEC, Inc. | Phase 2 |
| Completed | A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Soli NCT03792750 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Completed | Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Canc NCT03714958 | Centre Leon Berard | Phase 1 |
| Completed | MGD019 DART® Protein in Unresectable/Metastatic Cancer NCT03761017 | MacroGenics | Phase 1 |
| Completed | Feasibility, Acceptability and Preliminary Effects of the Spiritual Care Assessment and Intervention NCT03823313 | Indiana University | N/A |
| Unknown | Toripalimab as Monotherapy for Patients With Small Cell Carcinoma of Esophagus Who Failed Chemotherapy NCT03811379 | Sun Yat-sen University | Phase 2 |
| Suspended | Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malig NCT03722186 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Completed | POEM (Practice of Embracing Each Moment) Study (Delivery Science) NCT03751995 | Kaiser Permanente | N/A |
| Completed | Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma NCT03717298 | Catalysis SL | Phase 2 |
| Completed | A Study of WXFL10030390 in Patients With Advanced Solid Tumors or Lymphoma NCT03730142 | Shanghai Jiatan Pharmatech Co., Ltd | Phase 1 |
| Completed | Early Palliative Care on Quality of Life of Patients With Advanced Pancreas Cancer NCT03837132 | University of Manitoba | — |
| Unknown | Validation Studies of Biomarkers for Precision Radiation Oncology in Locally Advanced Solid Tumors NCT04110223 | Shandong Cancer Hospital and Institute | — |
| Completed | Extra Layer Of Support NCT03532997 | Duke University | N/A |
| Completed | Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab NCT03674567 | RAPT Therapeutics, Inc. | Phase 1 / Phase 2 |
| Completed | An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in P NCT03661632 | Bristol-Myers Squibb | Phase 1 |
| Withdrawn | Personalized Vaccine Generated by Autologous Dendritic Cells Pulsed With Autologous Whole Tumor Cell Lysate Tr NCT03671720 | Capital Medical University | EARLY_Phase 1 |
| Completed | COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. NCT03667716 | Compugen Ltd | Phase 1 |
| Active Not Recruiting | A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy NCT03391479 | University Health Network, Toronto | Phase 2 |
| Recruiting | Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain NCT03605771 | Grupo Español Multidisciplinar de Melanoma | — |
| Completed | Patient-centered Self-administered Acupressure for Fatigue Management in Chinese Advanced Cancer Patients NCT03610243 | The University of Hong Kong | N/A |
| Unknown | Uncertainty in Illness in Palliative Care: an Intervention for Family Caregivers NCT03518970 | Universidad Nacional de Colombia | N/A |
| Unknown | Immunotherapy of Advanced Cancer Using a Combination Nimotuzumab and NK Cells NCT03554889 | Hangzhou Cancer Hospital | Phase 1 |
| Completed | Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers NCT03568058 | Aaron Miller | Phase 1 |
| Terminated | A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML NCT03690154 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Phase 1 |
| Completed | Stress Management and Resilience Training (SMART) Intervention for Family Caregivers of Individuals With Advan NCT03565757 | Mayo Clinic | N/A |
| Terminated | CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma NCT03582618 | TaiRx, Inc. | Phase 2 |
| Completed | Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma NCT03526679 | National Taiwan University Hospital | Phase 1 / Phase 2 |
| Completed | Oral AMXT 1501 Dicaprate in Combination With DFMO NCT03536728 | Aminex Therapeutics, Inc. | Phase 1 |
| Unknown | 3D Prediction of Patient-Specific Response NCT03561207 | KIYATEC | — |
| Completed | An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or NCT03459222 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Completed | Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Sol NCT03510104 | Meryx, Inc. | Phase 1 |
| Completed | A Study of CS1003 in Subjects With Advanced Solid Tumors NCT03475251 | CStone Pharmaceuticals | Phase 1 |
| Completed | An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad NCT03335540 | Bristol-Myers Squibb | Phase 1 |
| Terminated | Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tum NCT03525392 | Ipsen | Phase 1 |
| Terminated | A Phase 1/2 Study of FS118 in Patients With Advanced Malignancies NCT03440437 | invoX Pharma Limited | Phase 1 / Phase 2 |
| Terminated | An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in NCT03444753 | Bristol-Myers Squibb | Phase 1 |
| Completed | AsiDNA (a DNA Repair Inhibitor) Administered IntraVenously in Advanced Solid Tumors NCT03579628 | Valerio Therapeutics | Phase 1 |
| Completed | Patient Activation Through Counseling, Exercise and Mobilization NCT03411200 | Herlev and Gentofte Hospital | N/A |
| Completed | Survival Expectations and Hope Among Cancer Patients at End-of-Life NCT03325218 | Duke-NUS Graduate Medical School | — |
| Completed | Emergency Medicine Palliative Care Access NCT03325985 | NYU Langone Health | N/A |
| Completed | Mirtazapine for Treatment of Cancer Associated Anorexia-cachexia NCT03254173 | Catherine Naseef Hunter | Phase 2 / Phase 3 |
| Terminated | An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants W NCT03446040 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Completed | The Feasibility of a Physical Activity Intervention for Advanced Multiple Myeloma Patients NCT04303091 | Dr. Nicole Culos-Reed | N/A |
| Completed | The PediQUEST Response Intervention Study NCT03408314 | Joanne Wolfe, MD, MPH | N/A |